MediciNova

MediciNova, Inc. is a development-stage biopharmaceutical company focused on acquiring, developing and commercializing high-quality small molecule therapeutics. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova has built a diversified portfolio of drug candidates each of which we believe has broad patent protection, a well-characterized and differentiated therapeutic profile and attractive commercial potential. MediciNova currently has eight compounds in clinical development for ten different indications representing large market opportunities. Medicinova’s pipeline includes treatments for asthma, Generalized Anxiety Disorder, interstitial cystitis, multiple sclerosis, status asthmaticus, preterm labor, cancer, urinary incontinence and thrombotic disorders. Several of these programs are in advanced clinical testing MediciNova’s strategy is to advance its clinical programs through the Phase II proof-of-concept stage and, at appropriate points of high-value inflection, to establish strategic alliances and partnerships to support Phase III clinical testing and commercialization of selected development programs. MediciNova may also retain certain promising compounds for further in-house development and potential commercialization. MediciNova’s executive management team has extensive global development, regulatory and commercial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. Headquartered in San Diego, California, MediciNova today has 24 employees.

Contact Details: 4350 La Jolla Village Drive Suite 950 San Diego CA 92122 United States of America Tel: (858) 373-1500 Fax: (858) 373-7000 Email: info@medicinova.com WWW: www.medicinova.com/

Loading...

Press Releases on MediciNova:
Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders	27th March, 2009	Biotechnology Value Fund, L.P.	Concurs with Avigen's decision to return capital to stockholders through liquidation A decisive victory for stockholder democracy SAN FRANCISCO, March 27 /PRNewswire/ -- Biotechnology Value
Leading Advisory Firm, PROXY Governance, Recommends Avigen Shareholders Vote on GOLD Card to Remove Incumbent Directors and Elect BVF's Stockholder-Oriented Nominees	23rd March, 2009	Biotechnology Value Fund, L.P.	NEW YORK, March 23 /PRNewswire/ -- Biotechnology Value Fund, L.P. ("BVF") today announced that PROXY Governance, widely recognized as a leading independent proxy advisory firm, has
Empirical Search Strategies Seeks Downside Protection Option at Avigen, Inc.	20th March, 2009	Empirical Search Strategies, L.P.	CHICAGO, March 20 /PRNewswire/ -- Empirical Search Strategies, LP. ("ESS"), the beneficial owner of approximately 2.3% of the Avigen, Inc.'s (Nasdaq: AVGN) outstanding common stock,
BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share	23rd January, 2009	BVF Acquisition LLC	NEW YORK, Jan. 23 /PRNewswire/ -- BVF Acquisition LLC (the "Purchaser"), a wholly owned subsidiary of Biotechnology Value Fund, L.P. ("BVF"), announced today that it has commenced
Biotechnology Value Fund, L.P. To Make Tender Offer For Any And All Outstanding Shares Of Avigen At $1.00 Per Share	15th January, 2009	Biotechnology Value Fund, L.P.	Tender Offer provides stockholders with a near-term cash alternative if BVF nominees are elected BVF reaffirms support for downside-protected merger with MediciNova NEW YORK, Jan. 15 /PRNewswire/ -

BioNews Results for MediciNova:
MediciNova, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released	PR inside:  Nov 13 2009 3:52PM Matching: medicinova
MediciNova Reports Third Quarter 2009 Results	Yahoo! Canada:  Nov 13 2009 12:21AM Matching: medicinova
MediciNova Reports Third Quarter 2009 Results	Interest!ALERT:  Nov 13 2009 12:18AM Matching: medicinova
MediciNova Reports Third Quarter 2009 Results	DMN Newswire:  Nov 12 2009 11:05PM Matching: medicinova
MediciNova Reports Third Quarter 2009 Results	NewsBlaze:  Nov 12 2009 10:29PM Matching: medicinova
Promote your company here: BioNewsCast - Press Release Distribution	→View more MediciNova news.

MediciNova Patents:
US Patent No.	Title
7429617	Phenoxyalkycarboxylic acid derivatives in the treatment of interstitial cystitis
7365224	Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propyl- phenoxy]butyric acid and methods of use
7153993	Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propyl- phenoxy]butyric acid
7064146	Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propyl- phenoxy]butyric acid and methods of use
7060854	Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propyl- phenoxy]butyric acid
→View more MediciNova patents.

MediciNova (MNOV) Financial information Links from Barchart
MNOV Quote from from Barchart.com
MNOV Chart from from Barchart.com
MNOV Profile from from Barchart.com
MNOV Opinion from from Barchart.com
→View more MediciNova finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 249 times since April 2007, the link to the organisation's website has been followed 58 times

Search for more companies in San Diego

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for MediciNova